WallStSmart

biote Corp (BTMD)vsDaVita HealthCare Partners Inc (DVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 7253% more annual revenue ($13.84B vs $188.16M). BTMD leads profitability with a 8.3% profit margin vs 5.7%. BTMD trades at a lower P/E of 5.1x. DVA earns a higher WallStSmart Score of 70/100 (B-).

BTMD

Hold

35

out of 100

Grade: F

Growth: 3.3Profit: 6.5Value: 8.3Quality: 7.0
Piotroski: 4/9Altman Z: 2.77

DVA

Strong Buy

70

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.22
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BTMDUndervalued (+47.8%)

Margin of Safety

+47.8%

Fair Value

$4.06

Current Price

$2.10

$1.96 discount

UndervaluedFair: $4.06Overvalued
DVASignificantly Overvalued (-16.7%)

Margin of Safety

-16.7%

Fair Value

$123.62

Current Price

$209.68

$86.06 premium

UndervaluedFair: $123.62Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BTMD2 strengths · Avg: 10.0/10
P/E RatioValuation
5.1x10/10

Attractively priced relative to earnings

Debt/EquityHealth
-1.9310/10

Conservative balance sheet, low leverage

DVA4 strengths · Avg: 9.0/10
Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Debt/EquityHealth
-17.5010/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.668/10

Growing faster than its price suggests

EPS GrowthGrowth
43.5%8/10

Earnings expanding 43.5% YoY

Areas to Watch

BTMD4 concerns · Avg: 2.5/10
Market CapQuality
$77.86M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Revenue GrowthGrowth
-8.3%2/10

Revenue declined 8.3%

EPS GrowthGrowth
-83.8%2/10

Earnings declined 83.8%

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.7%3/10

5.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BTMD

The strongest argument for BTMD centers on P/E Ratio, Debt/Equity.

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, Debt/Equity, PEG Ratio. PEG of 0.66 suggests the stock is reasonably priced for its growth.

Bear Case : BTMD

The primary concerns for BTMD are Market Cap, Return on Equity, Revenue Growth.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Key Dynamics to Monitor

BTMD carries more volatility with a beta of 1.66 — expect wider price swings.

DVA is growing revenue faster at 6.0% — sustainability is the question.

DVA generates stronger free cash flow (219M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DVA scores higher overall (70/100 vs 35/100). BTMD offers better value entry with a 47.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

biote Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

biote corp. The company is headquartered in Irvine, Texas.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Want to dig deeper into these stocks?